Clinical Trial

QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

Name: QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer — clinical trial record (NCT06917092)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: QLPPEC/GOG-003

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.

Trial Details

NCT Number	NCT06917092
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Endometrial Adenocarcinoma, Endometrial Cancer
Enrollment	30 participants
Start Date	2025-05-01
Primary Completion	2027-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2025-04-08